- Clinical Trials
- April 2024
- 60 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1188EUR$1,250USD£998GBP
- Report
- May 2024
- 135 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- August 2022
- 51 Pages
Global
From €1901EUR$2,000USD£1,597GBP
Tachycardia is a type of cardiovascular disorder characterized by an abnormally rapid heart rate. Tachycardia drugs are used to treat this condition and are typically classified as antiarrhythmic drugs. These drugs work by blocking or slowing down the electrical signals that cause the heart to beat too quickly. Commonly used tachycardia drugs include beta-blockers, calcium channel blockers, and antiarrhythmic agents. Beta-blockers are used to reduce the heart rate and blood pressure, while calcium channel blockers are used to reduce the force of the heart's contractions. Antiarrhythmic agents are used to regulate the electrical signals in the heart and prevent abnormal heart rhythms.
The tachycardia drug market is highly competitive, with a number of major pharmaceutical companies offering products for the treatment of this condition. Some of the leading companies in this market include Pfizer, Merck, Sanofi, Novartis, and GlaxoSmithKline. These companies offer a range of tachycardia drugs, including beta-blockers, calcium channel blockers, and antiarrhythmic agents. Show Less Read more